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OBJECTIVE: Placental dysfunction, including preeclampsia and fetal
growth restriction, is a leading contributor to maternal and fetal
morbidity and mortality. Development of effective prevention and
treatment strategies has been limited by lack of identiﬁcation of at-
risk pregnancies. We performed small RNA sequencing of maternal
serum microRNAs (miRNAs) to discover and independently verify
biomarkers differentially expressed in patients who later developed
preeclampsia.
STUDY DESIGN: Maternal serum was collected between 17-28 weeks
gestation in two cohorts: The high-risk UCSD Placenta Study (19
cases, 29 controls); and the Sera Prognostics PAPR Study (54 cases,
110 controls). Samples were divided into Discovery (2/3) and Veri-
ﬁcation sets (1/3). Cases and controls were matched for gestational
age (GA) at blood draw (Table 1). miRNAs were isolated and
sequenced to yield miRNA counts. Individual miRNAs and pairwise
ratios (reversals) were tested in blinded veriﬁcation.
RESULTS: Biomarker discovery and veriﬁcation were performed on
the entire GA range and for 3 GA windows: 170/7 - 215/7 (Early);
195/7 - 244/7 (Middle); and 222/7 - 280/7 (Late) weeks.
In Discovery, best performing miRNAs and reversals were selected
for each GA window. Performance was then conﬁrmed in blinded
Veriﬁcation (Table 2). 7/50 Early GA reversals had signiﬁcant AUCs
(mean Discovery AUC 0.78, mean Veriﬁcation AUC 0.79). 21/50
Late GA reversals had signiﬁcant AUCs (mean Discovery AUC 0.71,
mean Veriﬁcation AUC 0.68). Of biological importance, veriﬁed
reversals contained a high proportion of miRNAs that were strongly
expressed in placenta and/or encoded in the chr14q32 and chr19q13
miRNA clusters. miR-155-5p, present in 21 veriﬁed reversals, has
been reported to mediate repression of eNOS by TNFa, which is a
regulatory interaction associated with preeclampsia.
CONCLUSION: We identiﬁed and veriﬁed differentially abundant
miRNAs in maternal serum at 17-28 weeks GA in pregnancies that
later developed signs and symptoms of preeclampsia compared to
pregnancies with uncomplicated outcomes. Our ﬁndings suggest
that maternal serum miRNAs may be useful as biomarkers for
prediction of placental dysfunction and warrant validation in large
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generation antiepileptic drugs: retrospective cohort
study using claims database
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Yasser El-Sayed, Maurice L. Druzin
Stanford University, Stanford, CA
OBJECTIVE: Women with epilepsy are at increased risk for adverse
pregnancy outcomes. Since the 1990s, over 11 new antiepileptic
drugs (AEDs) have been introduced. We aimed to describe the use of
newer AEDs in pregnancy and differences in rates of obstetric
outcomes.
STUDY DESIGN: From the Truven Health MarketScan Commercial
Claims and Encounters Database (years 2011-14), we identiﬁed
women who had a delivery admission, outpatient pharmacy dis-
penses for newer generation AEDs (Table) and an indication of
epilepsy based on diagnosis codes during the 12 months prior to
delivery. Obstetric outcomes included preterm birth, cesarean de-
livery, postpartum hemorrhage, placental abruption, hypertensive
disorders of pregnancy, preterm labor, and severe maternal
morbidity (SMM). We described the prevalence of the use of newer
AEDs and rates of obstetric outcomes and absolute risk difference
compared to women without a diagnosis of epilepsy (Table).2019
